Evidence map›Paper›PMID 30907628›Full record

ArticleFuture medicinal chemistry2019

Structure-based drug discovery by targeting

Michio Kurosu

Abstract readEditorial
In one paragraph

Article in Future medicinal chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. DPAGT1-Perspective as an Anticancer Drug Target.Molecules (Basel, Switzerland) · 2025
    Review
  2. Article
  3. Concise Synthesis of Tunicamycin V and Discovery of a Cytostatic DPAGT1 Inhibitor.Angewandte Chemie (International ed. in English) · 2022
    Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Michio KurosuDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, 881 Madison Avenue, Memphis, TN 38163, USA.

Funding

Mechanistic details of key integral-membrane enzymes for antimicrobial discoveryR01GM114611 · NIGMS · CALIFORNIA INSTITUTE OF TECHNOLOGY · PI William M. Clemons, Michio Kurosu · 2016 to 2026
$4.2M
Targeting MraY: Synthesis and Validation of MraY InhibitorsR01AI084411 · NIAID · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI KUROSU, MICHIO · 2010 to 2013
$1.5M
NIAID NIH HHS R01 AI084411NIGMS NIH HHS R01 GM114611
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Drug DesignAnimalsBiosynthetic PathwaysDrug DiscoveryEnzyme InhibitorsHumansMolecular Docking SimulationN-AcetylglucosaminyltransferasesPolysaccharidesdolichyl-phosphate alpha-N-acetylglucosaminyltransferaseEnzyme InhibitorsN-AcetylglucosaminyltransferasesPolysaccharidesanticancer drugsco-crystal structuresDPAGT1inhibitorsstructure-based drug design

Identifiers

PMID30907628
PMCPMC6587103

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.